BioSpace News Archive

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced presentations of a pooled data analysis from its successful VANISH clinical development program during two October medical meetings.

Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672), announces today that the latest clinical and preclinical data of four NASH programs (ASC40/TVB-2640 co-authored with Sagimet Biosciences Inc., ASC41, ASC42 and ASC43F) will be presented in oral or poster presentation at The Liver Meeting® 2021 of American Association for the Study of Liver Diseases (AASLD).

New Real-World MAVENCLAD ® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients

Taysha Gene Therapies, Inc. today announced sponsored genetic testing for giant axonal neuropathy (GAN) in partnership with GeneDx, Inc.

Vera Therapeutics, Inc. announced today the upcoming presentation of clinical data for the Company’s lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy (IgAN).

Abeona Therapeutics Inc. today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021.

Apnimed today announced positive data across multiple endpoints from its Phase 2 randomized, double-blind, placebo-controlled, crossover clinical trial (Study APC-004) evaluating the efficacy and safety of AD109 as a treatment for patients with mild to moderate OSA.

Alnylam Pharmaceuticals, Inc. today announced the launch of Alnylam Challengers, a signature community impact program that will support bold and diverse organizations in their pursuit of developing new and sustainable solutions to address challenges in health equity.

Apnimed today announced positive data across multiple endpoints from a Phase 2 randomized, double-blind, placebo-controlled, four-period, single-dose crossover factorial clinical trial (APC-003), and a 28-day open-label extension study, evaluating AD109 as a treatment in patients with mild to severe OSA.

Resverlogix Corp., a world leader in epigenetics or gene regulation, announces that President and CEO Donald McCaffrey will be presenting virtually at the following conferences.